Immune-Related Adverse Events in Breast Cancer Patients Who Received Neoadjuvant Chemotherapy with Pembrolizumab: What Needs to Be Managed Before Surgery.

Lee J, Kang B, Moon JS, Um T, Choi JE, Lee M, Chae YS, Lee SJ, Lee IH, Lee SJ, Kang SH, Koh SA, Kang SH, Park KU, Kim H, Park HY.

Open source

DOI: 10.3390/cancers18060919
Published: 2026-03-12
Container: Cancers (Basel)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3390/cancers18060919,
  title = {Immune-Related Adverse Events in Breast Cancer Patients Who Received Neoadjuvant Chemotherapy with Pembrolizumab: What Needs to Be Managed Before Surgery.},
  author = {Lee J and  Kang B and  Moon JS and  Um T and  Choi JE and  Lee M and  Chae YS and  Lee SJ and  Lee IH and  Lee SJ and  Kang SH and  Koh SA and  Kang SH and  Park KU and  Kim H and  Park HY.},
  year = {2026},
  journal = {Cancers (Basel)},
  doi = {10.3390/cancers18060919},
  url = {https://doi.org/10.3390/cancers18060919}
}

RIS

TY  - JOUR
TI  - Immune-Related Adverse Events in Breast Cancer Patients Who Received Neoadjuvant Chemotherapy with Pembrolizumab: What Needs to Be Managed Before Surgery.
AU  - Lee J
AU  -  Kang B
AU  -  Moon JS
AU  -  Um T
AU  -  Choi JE
AU  -  Lee M
AU  -  Chae YS
AU  -  Lee SJ
AU  -  Lee IH
AU  -  Lee SJ
AU  -  Kang SH
AU  -  Koh SA
AU  -  Kang SH
AU  -  Park KU
AU  -  Kim H
AU  -  Park HY.
PY  - 2026
JO  - Cancers (Basel)
DO  - 10.3390/cancers18060919
UR  - https://doi.org/10.3390/cancers18060919
ER  -

APA

J, L., B, K., JS, M., T, U., JE, C., M, L., YS, C., SJ, L., IH, L., SJ, L., SH, K., SA, K., SH, K., KU, P., H, K., & HY., P. (2026). Immune-Related Adverse Events in Breast Cancer Patients Who Received Neoadjuvant Chemotherapy with Pembrolizumab: What Needs to Be Managed Before Surgery.. Cancers (Basel). https://doi.org/10.3390/cancers18060919

Source records

europe-pmc · retrieved 2026-09-27T05:32:56.602Z